Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study

Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m(2), paclitaxel 155 mg/m(2) (both day 1) and capecitabine 665 mg/m(2) twice daily (days 1–14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achiev...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Einbeigi, Z., Bergström, D., Hatschek, T., Malmberg, M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Libertas Academica 2008
Témata:
Short Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3161650/
https://ncbi.nlm.nih.gov/pubmed/21892328
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky